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Abstract
Background: Very late antigen 4 (VLA-4; integrin α4β1) is critical for transmigration of T helper (TH) 1 cells into the
central nervous system (CNS) under inflammatory conditions such as multiple sclerosis (MS). We have previously
shown that VLA-4 and melanoma cell adhesion molecule (MCAM) are important for trans-endothelial migration
of human TH17 cells in vitro and here investigate their contribution to pathogenic CNS inflammation.
Methods: Antibody blockade of VLA-4 and MCAM is assessed in murine models of CNS inflammation in conjunction
with conditional ablation of α4-integrin expression in T cells. Effects of VLA-4 and MCAM blockade on lymphocyte
migration are further investigated in the human system via in vitro T cell transmigration assays.
Results: Compared to the broad effects of VLA-4 blockade on encephalitogenic T cell migration over endothelial barriers,
MCAM blockade impeded encephalitogenic T cell migration in murine models of MS that especially depend on CNS
migration across the choroid plexus (CP). In transgenic mice lacking T cell α4-integrin expression (CD4::Itga4−/−), MCAM
blockade delayed disease onset. Migration of MCAM-expressing T cells through the CP into the CNS was restricted, where
laminin 411 (composed of α4, β1, γ1 chains), the proposed major ligand of MCAM, is detected in the endothelial
basement membranes of murine CP tissue. This finding was translated to the human system; blockade of MCAM
with a therapeutic antibody reduced in vitro transmigration of MCAM-expressing T cells across a human
fibroblast-derived extracellular matrix layer and a brain-derived endothelial monolayer, both expressing laminin α4.
Laminin α4 was further detected in situ in CP endothelial-basement membranes in MS patients’ brain tissue.
Conclusions: Our findings suggest that MCAM-laminin 411 interactions facilitate trans-endothelial migration of
MCAM-expressing T cells into the CNS, which seems to be highly relevant to migration via the CP and to potential
future clinical applications in neuroinflammatory disorders.
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Background
Multiple sclerosis (MS), a chronic disorder of the cen-
tral nervous system (CNS), is characterized by inflam-
matory lesions at early disease stages that are caused
by the infiltration of autoreactive immune cells into
the CNS [1, 2]. The inflammatory infiltrates, contain-
ing pathogenic T cells (T helper 1 (TH1) and TH17
cells), lead to demyelination and neuronal degener-
ation resulting in serious physical disability [3, 4].
Immune cell infiltration from the periphery into the
CNS, characteristic of the common relapsing-remitting
form of MS (RRMS), has been successfully targeted by
new therapies. In particular, the monoclonal antibody
natalizumab, which recognizes the integrin α4 subunit
of very late antigen-4 (VLA-4, integrin α4β1, CD49d/
CD29), has proven highly effective in reducing disease
progression by preventing leukocyte migration into the
CNS [5, 6]. VLA-4 plays a key role in the entry of
encephalitogenic T cells into the CNS by mediating the
initial rolling and adhesion steps of transmigration
through interaction with its receptor, vascular cell
adhesion molecule-1 (VCAM-1), expressed on
* Correspondence: nicholas.schwab@ukmuenster.de
1Clinic of Neurology with Institute of Translational Neurology, University of
Münster, Albert-Schweitzer-Campus-1, Building A01, 48149 Münster, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Breuer et al. Journal of Neuroinflammation  (2018) 15:236 
https://doi.org/10.1186/s12974-018-1276-4
endothelial cells of post-capillary venules upon inflam-
mation [7]. Even though VLA-4 has been shown to
play a crucial role in leukocyte trafficking over the
blood-brain barrier (BBB), animal studies revealed that
a subpopulation of TH17 cells, which represent a major
pathogenic T cell population in murine experimental
autoimmune encephalomyelitis (EAE) [8–10], can in-
vade the CNS in a VLA-4 independent manner. Recent
studies suggest that TH17 cells mainly rely on
leukocyte function-associated molecule-1 (LFA-1)
mediated firm adhesion to endothelial intercellular
adhesion molecule-1 (ICAM-1) to penetrate the chor-
oid plexus (CP) and enter into the CNS parenchyma or
the cerebrospinal fluid (CSF) space [11–13]. However,
LFA-1 is primarily involved in the firm adhesion to
endothelium and subsequent para-endothelial migra-
tion, and not in the initial rolling and adhesive steps
[14]. This poses the question of how the initial adhe-
sive steps are mediated in the encephalitogenic TH17
subpopulation and raises the possibility that different
immune cell-adhesion receptor interactions are
employed, depending on the route of entry into the
brain and the cellular barrier involved. Three import-
ant barriers restrict access of circulating immune cells
to the CNS parenchyma: the endothelial BBB in CNS
post-capillary venules, the epithelial-cerebrospinal fluid
barrier (BCSFB) at the CP, and the arachnoidea formed
by leptomeningeal cells [14–16].
Apart from LFA-1–ICAM-1-dependent penetration
of the CP by TH17 cells, we have recently shown that
adhesion of TH17 cells to an in vitro model of the BBB
in the absence of VLA-4 involves melanoma cell adhe-
sion molecule (MCAM; CD146) [17]. MCAM is an
extracellular adhesion molecule broadly expressed on
mesenchymally derived tissues [18]; in humans it has
also been reported to be expressed on a subpopulation
of IL-17-secreting CD4+ and CD8+ T cells (TH17 and
Tc17 cells, respectively) [18–25]. EAE experiments
performed in endothelial MCAM knockout mice have
shown reduced disease severity and reduced TH17 infil-
tration into the CNS, supporting a role for this mol-
ecule in the entry of encephalitogenic T cells into the
brain [26]. Laminin 411 (composed of α4, β1, and γ1
chains), a major component of endothelial basement
membranes [27], has been identified as a ligand for
MCAM, and MCAM-laminin 411 interactions have
been proposed to facilitate penetration of the BBB [22].
However, whether MCAM can contribute to TH17
penetration of other CNS barriers remains unclear.
The focus of the current study was, therefore, to eluci-
date the pathogenic relevance of MCAM compared to
VLA-4 in CNS inflammation in vivo by using different
murine models of MS (active and spontaneous experi-
mental autoimmune encephalitis (EAE)). Using antibody-
mediated blocking of VLA-4 and/or MCAM and T
cell-specific ablation of α4-integrin expression, we show
here that VLA-4 blockade abrogates the encephalitogenic
potential of T cells in a wide-ranging way by blocking
migration over endothelial barriers, whereas MCAM tar-
geting primarily restricts migration of TH17 cells over the
CP into the CNS by inhibiting MCAM-laminin α4 inter-
actions at the endothelial CP layer.
Methods
Mice
Eight- to 10-week-old C57BL/6 mice were purchased from
Harlan Laboratories (Horst, Netherlands). CD4-cre mice
were crossed with integrin Itga4flox/flox mice as previously
described [12, 28] to generate mice lacking integrin α4β1
specifically on T cells (CD4::Itga4−/−). Double-transgenic
mice (TCRMOG × IgHMOG mice or OSE/DEVIC mice)
expressing T- and B-cell receptors that recognize the same
myelin protein (MOG35–55) were generated by cross-
breeding transgenic mice carrying either a MOG35–55-spe-
cific T cell receptor (TCRMOG also referred to as 2D2 [29])
or a MOG35–55-specific B-cell receptor (IgH
MOG also re-
ferred to as Th [30]) as described previously [31, 32].
All animal experiments were approved by and con-
ducted in accordance with the laws and regulations of
the regulatory authorities for animal care and scientific
use in North Rhine-Westphalia, Germany (TVA-number
84-02.04.2014.A075).
Induction of EAE
EAE was induced in 6- to 8-week-old CD4::Itga4−/−
mice by subcutaneous injection of 200 μg MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK; Charité,
Berlin, Germany) emulsified in CFA containing 200 μg
Mycobacterium tuberculosis H37RA (Difco, MI, USA).
Pertussis toxin (400 ng; Alexis, San Diego, CA, USA) in
200 μl PBS was injected intraperitoneally (i.p.) on the
day of immunization (day 0) and 2 days later. Disease
severity was scored daily on a scale from 0 to 10 as pre-
viously described [33]: grade 0, no abnormality; grade 1,
limp tail tip; grade 2, limp tail; grade 3, moderate hind-
limb weakness; grade 4, complete hindlimb weakness;
grade 5, mild paraparesis; grade 6, paraparesis; grade 7,
heavy paraparesis; grade 8, tetraparesis; grade 9, quadri-
plegia or premoribund state; grade 10, death (experi-
mental autoimmune neuritis (EAN) score). Animals
were scored in a blinded fashion by two independent
observers. Disease onset was defined as a score greater
than or equal to 1.
Antibody treatment for in vivo blocking
The blocking antibodies anti-mMCAM (clone 15) (de-
scribed in [22]) and α4 integrin neutralizing antibody
(clone: PS/2, BioXCell, New Hampshire, USA) as well as
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the appropriate isotype control antibodies (rat IgG1, clone:
HRPN and rat IgG2b, clone: LTF-2; both BioXCell) were
used at a concentration of 10 mg/kg body weight. Mice
were treated every other day with i.p. injections of the
respective antibody from the indicated day on.
Cell preparation and flow cytometry
Single-cell suspensions of mouse spleens and peripheral
blood were prepared as described previously [33]. Mono-
nuclear cells were isolated from spinal cord and brain by
Percoll gradient [33] and cells were stained for 30 min at
4 °C with fluorescence-labeled mAbs in PBS containing
0.1% BSA. The following antibodies were used for the
detection of cell surface markers: anti-MCAM (clone:
ME-9F1), anti-CD3 (clone: 17A2), anti-CD4 (clone:
RM4-5), anti-NK1.1 (clone: PK136) (all from BioLegend,
Fell, Germany). Cells were assessed on a Gallios™ (Beckman
Coulter, Krefeld, Germany) and analyzed using Kaluza soft-
ware (Beckman Coulter).
Adoptive cell-transfer and staining of CP explants
For adoptive transfer experiments, splenocytes of 2D2
mice were isolated and cultured under MCAM
polarization conditions as described previously [22].
Briefly, cells were cultured for 5 days in RPMI (1640) sup-
plemented with 10% heat-inactivated fetal calf serum
(FCS), 1% penicillin-streptomycin, 1% L-glutamine, and
50 μM 2-mercaptoethanol (2-ME) in the presence of
10 μg/ml MOG35–55 peptide, 5 μg/ml anti-IFNγ (clone:
XMG1.2), 0.5 μg/ml anti-IL-4 (clone: 11B11, both
eBioscience), 5 ng/ml human TGFβ, and 20 ng/ml murine
IL-23 (both R&D systems, Wiesbaden, Germany). CD4+ T
cells were enriched by negative selection using MACS
(Miltenyi Biotec, Bergisch Gladbach, Germany), labeled
with 1 μM CellTracker™ Green CMFDA Dye (Thermo-
Fisher, Waltham, MA, USA) and adoptively transferred
into C57BL/6 recipient mice (2.4 × 106 CD4+ T cells per
mouse in 100 μl PBS) by i.v. injection. On days 2 and 5
after adoptive transfer choroid plexus explants were
stained as follows. After transferring the explanted chor-
oid plexus epithelia on glass slides, PBS + 0.3% tween20
was applied for 5 min followed by two washing steps in
PBS for 5 min. CP explants were fixed applying PBS
+ 2.2% PFA + 2% glucose + 0.02% sodium azide for
20 min at RT, rinsed in PBS, and additionally fixed using
100% methanol for 6 min. After two subsequent washes in
PBS for 5 min, unspecific binding was blocked by applying
PBS + 0.3% tween20 + 10% normal goat serum for 30 min
at RT and then stained with anti-laminin α4 (clone 377;
1:1000, rabbit anti mouse; [34]) in PBS + 0.3% tween20 for
2 h at RT. Subsequently, the stained CP explants were
washed twice for 5 min in PBS and stained using a sec-
ondary goat anti-rabbit antibody (1:100; Alexa fluor 568;
Life Technologies) for 1 h at RT. After another washing
series in PBS, cell nuclei were stained using DAPI (1 μg/
ml) in PBS for 5 min at RT, washed in PBS again, and
mounted in fluorescent mounting medium (Dako).
Cell culture and transmigration assays
Fibroblasts originated from primary human choroid
plexus epithelial cells (labeled as HCPEpiC) that were
purchased from ScienCell Research Laboratories
(Carlsbad, CA, USA) and were cultured in Epithelial
Cell Medium (EpiCM) supplemented with 2% fetal
bovine serum (FBS; ProVitro, Berlin, Germany) on
poly-L-lysine (2 μg/cm2; ScienCell Research Laborator-
ies). Cultured cells were characterized by real-time
quantitative PCR for expression of endothelial and epi-
thelial markers as well as expression of laminin α4.
Primary human brain microvascular endothelial cells
(HBMEC) were obtained from Pelobiotech GmbH (Pla-
negg, Germany) and maintained in microvascular endo-
thelial cell growth medium supplemented with FBS and
endothelial cell growth factor (ECGF) (ProVitro) on fi-
bronectin (Pelobiotech) as previously described [35].
Where indicated, HBMEC were treated with TNFα
(500 U/ml; R&D systems) for 16 h. For transmigration
assays, fibroblasts originating from HCPEpiC (1 × 105
cells) or HBMEC (1 × 105 cells) were seeded on poly-L-
lysine or fibronectin-coated membranes of Transwell in-
serts (6.5 mm Transwells Pore Polyester Membrane In-
sert; pore size = 3.0 μm; Corning, Lowell, MA, USA) and
grown to confluency. CD4+ T cells were purified from
whole blood of healthy donors (HD) using RosetteSep
CD4+ T cell enrichment cocktail (StemCell Technolo-
gies, Vancouver, BC, Canada). 2 × 105 CD4+ cells were
subsequently transferred to the endothelial cell layer and
were allowed to migrate in RPMI medium supplemented
with 2% B27 (Gibco, Eggenstein, Germany) as previously
described [36]. Transmigrated cells were collected from
the lower chamber after an incubation time of 4 h. CD4+
T cells from within the fibroblastic layer were obtained
by incubating the cell layer for 10 min at 37 °C with
Accutase (Sigma-Aldrich, Taufkirchen, Germany) and
cells were detached by rinsing with PBS. For quantifica-
tion, Calibrite beads (BD Biosciences, Heidelberg,
Germany) were added prior to harvesting the cells. The
relative cell numbers were determined by flow cytometry
and migrated cells were stained with anti-MCAM (clone:
P1H12; BD Pharmingen, Franklin Lakes, NJ, USA),
anti-CD4 (clone: OKT4), anti-CD11a (clone: HI111),
anti-CD49d (clone: 9F10), anti-CD62L (clone: DREG-
56), and anti-CD45RA (clone: HI100) (all from BioLe-
gend, Fell, Germany).
Blocking antibodies for transmigration assays
The blocking antibodies anti-VLA4 (anti-CD49d/natali-
zumab, Tysabri; Biogen Idec, Cambridge, MA, USA) and
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anti-MCAM (clone PRX003; Prothena Biosciences Inc.,
Dublin, Ireland) were used at a concentration of 10 μg/
ml. CD4+ lymphocytes were pre-incubated for 30 min
with the antibodies diluted in PBS before washing out of
the blocking antibodies and application to the transmi-
gration assays.
Real-time quantitative PCR
RNA was extracted from confluent monolayers of
HCPEpiC-derived fibroblasts or HBMEC using TRIzol
reagent (Invitrogen). cDNA was synthesized from 1 μg
of total RNA using a standard protocol with random
hexamer primers (ThermoScientifc). Real-time qPCR
was performed in a StepOnePlus cycler (Applied Biosys-
tems, Darmstadt, Germany) employing endogen control
primers for 18sRNA as well as a TaqMan Gene Expres-
sion Assays specific for human laminin α4, cytokeratin
18, VE-cadherin, vimentin, or PECAM1 (Applied Biosys-
tems, Darmstadt, Germany).
Immunofluorescence staining
For immunofluorescence studies, 4-μm-thick formalin-
fixed paraffin embedded (FFPE) murine brain sections
were stained for MCAM (CD146, rabbit monoclonal
IgG, clone: EPR3208; Abcam, Cambridge, UK). An amp-
lification with TSA Plus Biotin kit (PerkinElmer,
Waltham, USA) was performed according to the manu-
facturer’s instructions. As secondary antibodies goat-
anti-rabbit-HRP (IgG; LifeTechnologies, Carlsbad, USA)
and streptavidin AlexaFluor488 conjugate (Invitrogen,
Carlsbad, USA) were used. Sections were mounted in
Gold antifade containing 4′,6-diamidino-2-phenylindole
(DAPI, Invitrogen). Slides were analyzed on a BioRevo
microscope (BZ-9000, Keyence, Osaka, Japan) using the
BZ-II Analyzer software.
Six-μm-thick cryosections of murine brain tissue were
fixed with methanol and were stained for laminin α4
(clone 377b [37]), MECA32 antigen [38], and plectin
(Progen, Heidelberg, Germany).
For human CNS tissue, autopsy material from subjects
with MS was obtained from the Netherlands Brain Bank
(NBB). Immunofluorescence stainings were performed on
10 μm cryosections and paraformaldehyde-fixed confluent
monolayers of fibroblasts (derived from primary HCPE-
piC) with a monoclonal anti-human laminin α4 antibody
(clone 3D12 [39]) and an AlexaFluor488-labeled goat-
anti-mouse secondary antibody. In case of the fibroblastic
monolayers, an amplification step with TSA Plus Biotin
kit (PerkinElmer, Waltham, MA, USA) was performed ac-
cording to the manufacturer’s instructions. Tissues were
analyzed using a Zeiss LSM700 confocal microscope.
Images were analyzed using Volocity 6.3 software
(ImproVision).
Study approval
Studies on human samples were approved by the local eth-
ics committee (University of Muenster: Ethik-Kommission
der Ärztekammer Westfalen-Lippe und der Medizinischen
Fakultät der Westfälischen Wilhelms-Universität, registra-
tion number: 2010-245-f-S). All experiments were per-
formed according to the Declaration of Helsinki.
Statistical analysis
All values are presented as mean ± standard error of the
mean (SEM). Statistical significance was determined
using Student’s t test in the case of normally distributed
data; otherwise, a Mann-Whitney test was performed.
For comparisons between data of CD4+ subpopulations
from the same donor, the paired Student’s t test was
used. The two-way ANOVA followed by Bonferroni
post-test was applied for EAE experiments. P values
were considered significant if < 0.05 in all cases. Statis-
tical analyses were carried out using Prism (Version 5,
GraphPad, San Diego, CA, USA).
Results and discussion
MCAM blockade delays EAE disease onset in T cell-specific
integrin α4 knockout mice (CD4::Itga4−/−)
To investigate whether encephalitogenic CD4+ T cells
without functionally active VLA-4 can employ MCAM
to migrate into the CNS, we induced EAE in transgenic
mice lacking α4-integrin expression on T cells
(CD4::Itga4−/−) in the presence or absence of a function-
blocking antibody to MCAM. MOG35–55 immunized
CD4::Itga4−/− mice developed a mild and clinically atyp-
ical EAE, as previously reported [12] (Fig. 1a). Applica-
tion of anti-MCAM to CD4::Itga4−/− mice every second
day after MOG35–55 immunization commencing on day
0 resulted in a delay in disease onset (Fig. 1a, b and
Table 1), but no change in disease severity. This suggests
that in the absence of α4-integrin, MCAM blocking de-
lays but does not completely prevent CD4+ TH17 entry
into the CNS parenchyma. Former studies have shown
that the chemokine receptor CCR6, which like MCAM
is selectively upregulated in polarized murine TH17 cells
[10, 22], is essential for CNS trafficking of TH17 cells to
the CP. CCR6+ TH17
+ cells are considered to represent
the first wave of leukocyte infiltration required for the
subsequent recruitment of other inflammatory cells
(TH1 cells) across post-capillary venules and induction
of disease symptoms [10]. TH17 cells are further able to
access the CNS parenchyma independently of VLA-4
and MOG35–55 immunized mice lacking α4-integrin ex-
pression on T cells (CD4::Itga4−/−) exhibit marked im-
mune cell infiltration within the plexus epithelium [12],
indicating that in the absence of α4-integrin encephalito-
genic T cells are recruited via the choroid plexus into
the CNS. These findings and the observed delay in EAE
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onset upon MCAM blockade suggest that, besides
CCR6, MCAM might be crucial for the initial infiltra-
tion of encephalitogenic TH17 cells via the CP. Further,
our recent observation of a specific accumulation of
MCAM-expressing lymphocytes in the CSF of patients
with MS that are under long-term natalizumab therapy
(VLA-4 blockade) [17] suggests also that MCAM-ex-
pressing lymphocytes migrate over the CP into the
CNS.
Blockade of MCAM might possibly impact migration
into the CNS via blocking of endothelial MCAM, as
entry of encephalitogenic T cells into the brain is
reduced in endothelial MCAM knockout mice [26];
however, flow cytometry performed on day 22 post
immunization with an anti-mMCAM, antibody recog-
nizing an epitope distinct from the therapeutic anti-
body, showed that administration of the MCAM
neutralizing antibody resulted in lower expression of
MCAM on natural killer (NK) cells (Additional file 1:
Figure S1a) and CD4+ T cells both in the periphery and
the CNS (quantification is shown in Fig. 1c and repre-
sentative flow cytometric analysis in Fig. 1e), suggesting
Fig. 1 MCAM blockade delays EAE onset in T cell-specific Itga4 knockout mice (CD4::Itga4−/−). a Development of active EAE in CD4::Itga4−/− mice
treated every other day after MOG35–55 immunization with anti-MCAM (clone 15) neutralizing antibody or isotype control antibody. Mean clinical
EAN scores ± SEM of three independent experiments over time are shown; *P < 0.05; green highlighted areas: P < 0.1 (b) The average day
of disease onset, defined as the first day with a score greater than or equal to 1, is shown as mean ± SEM. Percentages of MCAM CD4+ T
cells (c) isolated from the spleen, blood, spinal cord, and brain of isotype control or anti-MCAM-treated mice were quantified by flow
cytometry on day 22 post MOG35–55 immunization. Correlation analyses between the clinical score (EAN) and percentages of MCAM-expressing CD4
+
T cells (d) in brains of isotype control (black dots) and anti-MCAM-treated mice (gray dots) on day 22 post immunization shows a positive correlation
for CD4+T cells (Spearman r = 0.7513; P = 0.01). e Representative flow cytometric analyses of MCAM+ CD4+ T cells are shown for isotype control (upper
panel) or anti-MCAM-treated mice (lower panel)
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shedding or downregulation of MCAM on peripheral
immune cells.
In mice, contrary to humans, MCAM is strongly
expressed on NK cells [40], which might be a reason for
the more pronounced downregulation in the percentages
of MCAM+ NK cells compared to the slight effect on
MCAM+ T cells. In CD4::Itga4−/− mice-independent of
the treatment, percentages of MCAM-expressing CD4+
cells in the brain correlated with the clinical score
(Spearman r = 0.7513; P = 0.01) (Fig. 1d), whereas
MCAM-expressing NK cell proportions in the brain did
not correlate with clinical score (Spearman r = − 0.4427;
P = 0.2) (Additional file 1: Figure S1b), indicating that
the severity of EAE depends on the amount of MCAM+
CD4+ T cells in the brain. As CD4+ T cells are the pri-
mary pathogenic T cells in EAE [41], this suggests that
antibody blocking of MCAM affects either MCAM-ex-
pressing TH17 cell numbers in the periphery or their
entry into the CNS and, thereby, EAE induction.
Blockade of VLA-4 and MCAM in a spontaneous mouse
model of MS (“Devic” mice)
To assess whether anti-MCAM effects are specific to
TH17 versus TH1-induced inflammation, we utilized a
spontaneous mouse model of MS (“Devic” mice), which
shows largely optic nerve and spinal cord leukocyte infil-
tration and is mainly characterized by a TH1 cytokine
profile [31, 32, 42]. Devic mice are a double-transgenic
mouse strain, expressing T and B cell receptors that
recognize the same autoantigen (MOG), in which
around 50% of the double-transgenic offspring spontan-
eously develop a paralytic disease reminiscent of a subset
of neuromyelitis optica patients. Devic mice were treated
every second day from day 16 after birth with either
anti-VLA4, anti-MCAM, or both antibodies; control
mice were treated with the appropriate isotype control
antibodies. VLA-4 blockade largely protected mice from
the development of paralytic disease (Fig. 2a and
Table 1), whereas blockade of MCAM resulted in re-
duced disease incidence and severity (Fig. 2b and
Table 1). Blockade of both VLA-4 and MCAM did not
show an additive effect compared to VLA-4 blockade
alone (Fig. 2c and Table 1). These results are consistent
with the reported high expression of VLA-4 on TH1 cells
and the comparatively low VLA-4 levels on MCAMhigh
TH17 cells [12, 22]. In addition, the data suggest that the
effects of anti-MCAM treatment are most pronounced
in TH17-mediated EAE and therefore affect TH17 traf-
ficking to the brain. Previous experiments employing
murine models of MS with encephalitogenic T cells ex-
pressing VLA-4 showed that administration of a MCAM
blocking antibody affected disease progression during re-
mission [22–24]. However, mice with Devic’s disease
normally do not enter remission, which could explain
why we did not observe effects of the MCAM treatment
in the late stage of the disease.
In order to corroborate the influence of MCAM in
CNS inflammation in the Devic model, we performed
histological analyses of the CP tissue to investigate
whether MCAM blockade might impact migration into
the CNS via blocking of endothelial MCAM. However,
endothelial MCAM expressing cells could easily be de-
tected in the CP tissue of mice treated with anti-MCAM
blocking antibody or with a synergistic blockade of
MCAM and VLA-4 (Fig. 2d), suggesting that this
anti-MCAM neutralizing antibody does not have any
impact on endothelial MCAM and acts on peripheral
immune cells.
To assess the relevance of MCAM expression on T
cells for their transmigration across the CP, we per-
formed histological stainings of laminin α4, the proposed
major ligand of MCAM, in murine CP tissue. Double
staining of CP tissue from healthy control mice for
endothelial or epithelial markers together with the
MCAM ligand laminin α4 revealed laminin α4 staining
exclusively in association with the MECA32+ endothelial
cells of the CP (Fig. 3a) located between the plectin+ epi-
thelial cell layers (Fig. 3b) [43, 44]. Blockade of MCAM
might therefore ameliorate CNS inflammation by pre-
venting migration of MCAM expressing cells across the
endothelial CP layer on their way into the CNS.
In a proof-of-concept experiment, we transferred fluo-
rescently labeled myelin oligodendrocyte glycoprotein-
specific TCR-transgenic T cells (2D2 T cells), differenti-
ated in vitro with a protocol that induces high percent-
ages of MCAM expressing cells [22], into C57BL/6
Table 1 Summary of EAE incidence, onset, and maximum disease
severity in different murine models of MS upon antibody mediated
blocking of VLA-4, MCAM, or VLA-4 and MCAM
Mouse Treatment Incidence Age (days)/day
of onset
Cumulative
score
Integrin
α4−/−
Anti-MCAM 3/13
(23%)
19.3 ± 0.66 0.21 ± 0.12
Integrin
α4−/−
Isotype (MCAM) 6/16
(38%)
16.8 ± 0.65 0.38 ± 0.14
Devic Anti-VLA-4 1/11 (9%) 39 ± 0 0.01 ± 0.01
Devic Isotype (VLA-4) 7/11
(64%)
33.7 ± 1.5 0.58 ± 0.16
Devic Anti-MCAM 9/22
(41%)
34.3 ± 1.6 0.65 ± 0.19
Devic Isotype (MCAM) 12/21
(57%)
36.1 ± 1.4 0.79 ± 0.19
Devic Anti-VLA-4/
MCAM
2/11
(18%)
35.5 ± 3.5 0.09 ± 0.07
Devic Isotype (VLA-4/
MCAM)
9/11
(82%)
30 ± 1.7 1.54 ± 0.09
The age/day of onset and the cumulative score are means ± SEM
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recipient mice. Immunofluorescence staining of cortical
explants at days 2 and 5 after transfer revealed individual
MCAM expressing CD4+ T cells in the CP, providing
first evidence that MCAM-expressing T cells can mi-
grate through the CP and potentially into the CNS
(Representative images are shown in Additional file 2:
Figure S2; numbers of transferred cells, that were de-
tected in the CP: mouse 1: 23; mouse 2: 19; mouse 3:
17). Staining of laminin α4 in cortical explants con-
firmed further the localization of the MCAM ligand to
endothelial basement membranes of the CP (Fig. 3c–e).
Enhanced migration of human MCAM-expressing T cells
across endothelial and extracellular matrix barriers is
dependent on MCAM-laminin 411 interactions
To further investigate whether MCAM has an effect on
lymphocyte migration over CP endothelial barriers, we
performed in vitro T cell transmigration assays using
primary human brain-derived microvascular endothelial
cells (HBMECs) and choroid plexus fibroblasts (labeled as
“HCPEpiC”) (characterization of the cells is shown in
Additional file 3: Figure S3). We have previously shown
that laminin α4 can be expressed by fibroblasts in different
tissues but is deposited in subjacent endothelial basement
membranes [27] and that it is also expressed by cultured
HBMECs [17]. Immunofluorescent staining confirmed
that laminin α4 is present on cultured HCPEpiC-derived
fibroblasts in vitro (Fig. 4a), and MCAM blockade indeed
restricted transmigration of MCAM-expressing T cells
(Fig. 4b). The proportion of MCAM+ cells among CD4+ T
cells was enriched in the fraction of cells that transmi-
grated the HCPEpiC-derived fibroblasts layer, compared
to the initial (ex vivo) CD4+ T cell fraction, but was signifi-
cantly reduced when the CD4+ lymphocytes were
pre-incubated with a MCAM blocking antibody, either
alone or together with anti-VLA-4. Moreover, analysis of
Fig. 2 MCAM and VLA4 blockade in a model of spontaneous EAE. Development of spontaneous EAE-like disease in Devic mice that were either
treated with (a) anti-VLA4 (clone PS/2), (b) anti-MCAM (clone 15), (c) anti-MCAM and anti-VLA4 antibodies, or the respective isotype control antibodies.
Mice were treated every second day from day 16 after birth. Littermates were used for the treatment with either the respective blocking antibody or
the isotype control. Mean clinical EAN scores ± SEM of three independent experiments over time are shown; *P < 0.05; green highlighted areas: P < 0.1.
(d) Immunofluorescence staining of MCAM (green) in choroid plexus tissue obtained from Devic mice treated with anti-VLA-4, anti-MCAM, or anti-
MCAM/VLA-4 neutralizing antibodies. Nuclear staining (DAPI) is shown in blue. Scale bars are 10 μm
Breuer et al. Journal of Neuroinflammation  (2018) 15:236 Page 7 of 12
fibroblastic layer following the transmigration period, re-
vealed enrichment of MCAM+ CD4+ T cells within the
cell layer (Fig. 4c), suggesting adherence of MCAM+ lym-
phocytes to laminin α4 in the deposited extracellular
matrix during their migration through the cell layer.
MCAM blockade led to marked accumulation of MCAM+
CD4+ T cells within the cell layer (Fig. 4c), suggesting that
the cells can still adhere to the fibroblastic cell layer, but
require MCAM-mediated processes for efficient transmi-
gration. This was substantiated by the results of transmi-
gration over both TNF-α inflamed or non-inflamed
HBMECs, which also revealed reduced MCAM+ CD4+ T
cell transmigration over an endothelial layer in presence
of a MCAM blocking antibody (Fig. 4d).
To determine whether these in vitro findings are also
relevant to the human in vivo system, we stained human
CP tissue from one MS patient for laminin α4. We de-
tected high laminin α4 expression in association with
the endothelial layer of the CP, whereas no laminin α4
staining was detectable on the epithelial layer (Fig. 4e).
The pattern of laminin α4 localization, therefore, sup-
ports the hypothesis that MCAM-laminin α4 interac-
tions facilitate MCAM+CD4+ T cell penetration of the
CP endothelial layer and thereby entry into the CNS
during neuro-inflammation.
The differential effects of blocking VLA-4 and/or
MCAM in active EAE and in the spontaneous EAE
model suggest that targeting VLA-4 restricts most en-
cephalitogenic T cells from migrating into the CNS,
while blockade of MCAM more specifically inhibits
TH17 cell migration into the CNS via the CP endothe-
lium. Effects of MCAM blockade are particularly pro-
nounced in murine models of MS that depend on CNS
migration across the CP, such as in the case of mice
lacking α4-integrin expression on T cell. This is in ac-
cordance with our previous observation of a specific ac-
cumulation of MCAM+ CD4+ T cells in the CSF of MS
patients with long-term Natalizumab therapy (VLA-4
blockade) [17], suggesting that MCAM+ CD4+ lympho-
cytes preferentially migrate over the CP into the CNS.
This may be further enhanced by the high expression of
the chemokine receptor CCR6, a characteristic marker
of the encephalitogenic TH17 cells [10], which binds to
CCL20 expressed on the choroid plexus epithelium in
mice [45] and confirmed here for human tissue (see
Additional file 4: Figure S4).
Leukocytes that are recruited to the CP and thereby
into the CNS have to migrate through the endothelium
and underlying basement membrane before they can mi-
grate through the epithelial barrier into the CSF. Here,
we show that MCAM is required for migration of an en-
cephalitogenic MCAM+ CD4+ subpopulation of T cells
into the CP, as cells without MCAM showed reduced
migration across both endothelial and fibroblastic lam-
inin 411 expressing layers in vitro and reduced CNS in-
filtration in vivo.
Accordingly, laminin α4 was localized to basement
membranes underlying the choroidal endothelium, but
not choroidal epithelium, suggesting that MCAM-laminin
411 interactions mediate the initial choroidal endothelium
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Fig. 3 Laminin α4 localization to choroid plexus endothelial
basement membranes. C57BL/6 mouse choroid plexus samples
immunofluorescently stained for (a) laminin α4 (green) and MECA32
antigen as an endothelial cell marker (red) or (b) laminin α4 (red)
and plectin to mark choroid epithelium (green), demonstrating
colocalization of laminin α4 with the MECA32+ blood vessels located
beneath the epithelial layers. Cell nuclei are counterstained with
DAPI (blue). Higher magnifications of the boxed areas are shown in
the lower panels. Bars are 100 μm (upper panels) and 10 μm (lower
panels), respectively. c–e Immunofluorescence staining of choroid
plexus explants of C57BL/6 mice for (c) laminin α4 (red) and PECAM
(green), (d) laminin α4 (green) and MCAM (red), and (e) PECAM (green)
and MCAM (red). Nuclear staining (DAPI) is shown in blue, and left
panels represent control stainings. Scale bars: 10 μm
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Fig. 4 MCAM-laminin α4 interactions mediate lymphocyte transmigration across human endothelial and fibroblastic layers. a Immunofluorescence
staining of cultured fibroblasts derived from primary human choroid plexus cells (HCPEpiC) with anti-laminin α4 (green); cell nuclei are counterstained
with DAPI (blue). Bar is 50 μm. b In vitro transmigration of CD4+ lymphocytes through the fibroblastic plus connective tissue layer in a modified
Boyden chamber assay. Shown are the percentages of MCAM+ CD4+ T cells before inclusion in the transmigration assay (ex vivo) and after
transmigration without (w/o) blocking antibody or with VLA4, MCAM, or MCAM and VLA4 blocking antibodies. Data are from four independent
experiments. c Percentages of MCAM+ CD4+ T cells retained in the HCPEpiC layer in the absence (w/o) or presence of MCAM blocking antibody
compared to the original sample (ex vivo). Data are from four independent experiments. d Percentages of MCAM+ CD4+ T cells before and after
transmigration of a HBMEC layer without (w/o) blocking antibody or with MCAM blocking antibody, under non-inflamed or inflammatory conditions
(+TNFα). Data are from three independent experiments. e Laminin α4 (green) staining of human choroid plexus tissue from MS CNS samples. Nuclear
staining (DAPI) is shown in blue, and the epithelial cell marker cytokeratin 18 (CK18) is shown in red. Bar is 50 μm
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crossing in vivo. The differential expression of laminin
isoforms as a “doorway” for leukocyte migration across
endothelial of post-capillary venules in the CNS paren-
chyma has previously been reported [34, 46, 47] and,
therefore, a similar concept might also apply for the chor-
oidal endothelium.
Importantly, by interfering with migration over the CP
endothelium, MCAM blockade might have a specific ef-
fect on disease initiation. Others have previously re-
ported the CP as the site of T cell entry into the CNS
during immune surveillance and at first stages of
neuro-inflammation [10].
However, besides the CP, there are other entry routes
into the CNS, such as through the circumventricular or-
gans or through the leptomeninges, both of which are
widely considered to be important in acute inflammation
and perpetuation of CNS disease. In a rat EAE model,
the leptomeninges was recently identified as an import-
ant checkpoint for T cell infiltration of the CNS, where
effector T cells can enter the CSF and eventually invade
the parenchyma [48]. These alternative entry routes into
the CNS, which were not assessed in this study, might
be the reason why a complete prevention of auto-
immune CNS inflammation upon MCAM blockade in
the absence of VLA-4 was not be observed.
Conclusions
Our results indicate that targeting MCAM results in an
overall lower, but more specific clinical improvement
compared to targeting VLA-4 and seems to affect mainly
TH17 cells. This suggests that therapeutic blocking of
MCAM might be advantageous over VLA-4 blocking, in
terms of the balance of blocking pathogenic cells versus
immune surveillance mechanisms and may, therefore,
have fewer adverse effects. Hence, in case of a clear TH17
pathology, blocking of MCAM, instead or in addition, to
VLA-4 or basic therapies such as anti-interferon treat-
ment might represent a new therapeutic avenue.
Additional files
Additional file 1: Figure S1. MCAM expression on NK cells does not
correlate with clinical score. Percentages of MCAM-expressing NK1.1+
cells (a) isolated from the spleen, blood, spinal cord, and brain of isotype
control or anti-MCAM-treated mice were quantified by flow cytometry on
day 22 post MOG35–55 immunization. Correlation analyses between the
clinical score (EAN) and percentages of MCAM-expressing NK1.1+ cells (b) in
brains of isotype control (black dots) and anti-MCAM-treated mice (gray
dots) on day 22 post immunization show no correlation for NK1.1+ cells
(Spearman r = − 0.4427; n.s.). (JPG 1119 kb)
Additional file 2: Figure S2. MCAM-expressing CD4+ T cell migrate
through the choroid plexus into the CNS. Representative images of
adoptively transferred myelin oligodendrocyte glycoprotein-specific
TCR-transgenic T cells (2D2 T cells) in whole-mount murine choroid
plexus samples. 2D2 T cells were differentiated in vitro for 5 days under
MCAM polarizing conditions (MOG35–55, TGFβ, IL-23), CMFDA-labeled,
and transferred by i.v. injection to three C57BL/6 recipient mice.
Immunofluorescence staining of choroid plexus explants on day 2
(mouse 1; a) and day 5 (mouse 2, 3; b, c) after adoptive transfer for
CMFDA+ CD4+ T cells (green), and nuclei (blue; DAPI). Scale bars:
10 μm. (TIF 913 kb)
Additional file 3: Figure S3. Characterization of human brain-derived
microvascular endothelial cells and fibroblasts derived from human
choroid plexus cells. mRNA levels of laminin α4, cytokeratin 18 (CK18),
PECAM1, VE-cadherin, and vimentin in primary human brain-derived
microvascular endothelial cells (HBMEC) and fibroblasts originated from
primary human choroid plexus epithelial cells (labeled as HCPEpiC) were
quantified by real-time PCR, revealing the lack of epithelial markers by
HCPEpiC and confirming their fibroblastic nature. n.d. = not detected (TIF
4578 kb)
Additional file 4: Figure S4. CCL20 localization on human choroid
plexus tissue. CCL20 staining (green) on human choroid plexus
epithelium in control CNS tissue samples. Nuclear staining (DAPI) is
shown in blue. Scale bars = 100 μm. (TIF 6336 kb)
Abbreviations
BBB: Blood-brain barrier; CNS: Central nervous system; CP: Choroid plexus;
CSF: Cerebrospinal fluid; EAE: Experimental autoimmune encephalomyelitis;
HBMECs: Human brain-derived microvascular endothelial cells; HCPEpiC: Human
choroid plexus epithelial cells; ICAM-1: Intercellular adhesion molecule-1;
LFA-1: Leukocyte function-associated molecule-1; MCAM: Melanoma cell
adhesion molecule; MOG: Myelin oligocendrocyte glycoprotein; MS: Multiple
sclerosis; NK: Natural killer; TH: T helper; VCAM-1: Vascular cell adhesion
molecule-1; VLA-4: Very late antigen-4
Acknowledgements
We thank Petra Babucke, Barbara Meyring (Department of Neurology,
Münster) and Claudia Kemming (Department of Neuropathology) for
excellent technical assistance.
Funding
This study was funded by the German Research Foundation (DFG) Grant
CRC128 Project B1 to NS and AZ, Project A09/A10/Z2 to HW, A07 to TKo,
B07/Z02 to TKu, B03 to LS, Prothena Biosciences Inc., the Interdisziplinäre
Zentrum für Klinische Forschung (IZKF) Münster (Wie3/009/16) to NS and
HW, and the Kompetenznetz Multiple Sklerose (Competence Network for
Multiple Sclerosis) funded by the Federal Ministry of Education and
Research (FKZ 01GI1308B 01GI0907) to HW and ToKo. This work was
partially supported by the DFG Cluster of Excellence EXE1003.
Availability of data and materials
All data generated or analyzed during this study are included in this published
article. The datasets used and/or analyzed during the current study are also
available from the corresponding author on reasonable request.
Authors’ contributions
JB, EK, MJH, TSH, JS, LZ, and SH performed experiments and analyzed the
data. NS, LS, KF, TKo, AZ, and HW conceived and designed the study. TKu
contributed to the data acquisition and interpretation. JB, LS, and NS wrote
the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All animal procedures were approved by and conducted in accordance
with the laws and the regulations of the regulatory authorities for animal
care and scientific use in North Rhine-Westphalia, Germany. Studies on
human samples were approved by the local ethics committee and performed
according to the Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
JB, EK, MJH, TSH, JS, LZ, SH, TKo, AZ, and LS have nothing to declare. KF is an
employee of Prothena Biosciences Inc. TKu has received honoraria from Novartis
and EXCEMED. HW has received honoraria and consultation fees from Biogen. NS
has received travel support from Sanofi-Genzyme and Novartis.
Breuer et al. Journal of Neuroinflammation  (2018) 15:236 Page 10 of 12
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Clinic of Neurology with Institute of Translational Neurology, University of
Münster, Albert-Schweitzer-Campus-1, Building A01, 48149 Münster,
Germany. 2Institute of Physiological Chemistry and of Pathobiochemistry,
University of Münster, Münster, Germany. 3Cells-in-Motion Cluster of
Excellence, University of Münster, Münster, Germany. 4Department of
Anesthesiology, University of Münster, Münster, Germany. 5Prothena
Biosciences Inc., South San Francisco, CA, USA. 6Department of Neurology,
Technical University of Munich, Munich, Germany. 7Munich Cluster for
Systems Neurology (SyNergy), Munich, Germany. 8Department of
Neuropathology, University of Münster, Münster, Germany.
Received: 28 March 2018 Accepted: 10 August 2018
References
1. Alberio L, Dale GL. Review article: platelet-collagen interactions: membrane
receptors and intracellular signalling pathways. Eur J Clin Investig. 1999;29:
1066–76.
2. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180–8.
3. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis.
Nat Rev Immunol. 2015;15:545–58.
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its
pathogenesis. N Engl J Med. 2006;354:942–55.
5. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH,
Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. A randomized, placebo-
controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med.
2006;354:899–910.
6. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N.
Prevention of experimental autoimmune encephalomyelitis by antibodies
against alpha 4 beta 1 integrin. Nature. 1992;356:63–6.
7. Steiner O, Coisne C, Cecchelli R, Boscacci R, Deutsch U, Engelhardt B, Lyck R.
Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-
resistant T cell arrest, polarization, and directed crawling on blood-brain
barrier endothelium. J Immunol. 2010;185:4846–55.
8. Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Nowak N,
Beyer M, Mayer G, et al. The nuclear receptor PPAR gamma selectively
inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS
autoimmunity. J Exp Med. 2009;206:2079–89.
9. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev
Immunol. 2009;27:485–517.
10. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli
A, Lanzavecchia A, Engelhardt B, Sallusto F. C-C chemokine receptor 6-
regulated entry of TH-17 cells into the CNS through the choroid plexus is
required for the initiation of EAE. Nat Immunol. 2009;10:514–23.
11. Glatigny S, Duhen R, Arbelaez C, Kumari S, Bettelli E. Integrin alpha L
controls the homing of regulatory T cells during CNS autoimmunity in the
absence of integrin alpha 4. Sci Rep. 2015;5:7834.
12. Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, Hemmer
B, Korn T. Th17 lymphocytes traffic to the central nervous system
independently of alpha4 integrin expression during EAE. J Exp Med. 2011;
208:2465–76.
13. Rothhammer V, Muschaweckh A, Gasteiger G, Petermann F, Heink S, Busch
DH, Heikenwalder M, Hemmer B, Drexler I, Korn T. alpha4-integrins control
viral meningoencephalitis through differential recruitment of T helper cell
subsets. Acta Neuropathol Commun. 2014;2:27.
14. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach
the blood-brain barriers. Trends Immunol. 2012;33:579–89.
15. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid
barriers: function and dysfunction. Semin Immunopathol. 2009;31:497–511.
16. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the
central nervous system. J Clin Invest. 2010;120:1368–79.
17. Schneider-Hohendorf T, Rossaint J, Mohan H, Boning D, Breuer J, Kuhlmann
T, Gross CC, Flanagan K, Sorokin L, Vestweber D, et al. VLA-4 blockade
promotes differential routes into human CNS involving PSGL-1 rolling of T
cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014;211:1833–46.
18. Dagur PK, McCoy JP Jr. Endothelial-binding, proinflammatory T cells
identified by MCAM (CD146) expression: characterization and role in
human autoimmune diseases. Autoimmun Rev. 2015;14:415–22.
19. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E.
Phenotypical and functional characterization of T helper 17 cells in multiple
sclerosis. Brain. 2009;132:3329–41.
20. Dagur PK, Biancotto A, Stansky E, Sen HN, Nussenblatt RB, McCoy JP.
Secretion of interleukin-17 by CD8+ T cells expressing CD146 (MCAM). Clin
Immunol. 2014;152:36–47.
21. Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB,
McCoy JP Jr. MCAM-expressing CD4(+) T cells in peripheral blood secrete
IL-17A and are significantly elevated in inflammatory autoimmune diseases.
J Autoimmun. 2011;37:319–27.
22. Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, Mocci
S, Seto P, You M, Larochelle C, et al. Laminin-411 is a vascular ligand
for MCAM and facilitates TH17 cell entry into the CNS. PLoS One. 2012;
7:e40443.
23. Larochelle C, Cayrol R, Kebir H, Alvarez JI, Lecuyer MA, Ifergan I, Viel E,
Bourbonniere L, Beauseigle D, Terouz S, et al. Melanoma cell adhesion
molecule identifies encephalitogenic T lymphocytes and promotes their
recruitment to the central nervous system. Brain. 2012;135:2906–24.
24. Larochelle C, Lecuyer MA, Alvarez JI, Charabati M, Saint-Laurent O, Ghannam
S, Kebir H, Flanagan K, Yednock T, Duquette P, et al. Melanoma cell
adhesion molecule-positive CD8 T lymphocytes mediate central
nervous system inflammation. Ann Neurol. 2015;78:39–53.
25. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the
blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585:3770–80.
26. Duan H, Xing S, Luo Y, Feng L, Gramaglia I, Zhang Y, Lu D, Zeng Q, Fan K,
Feng J, et al. Targeting endothelial CD146 attenuates neuroinflammation by
limiting lymphocyte extravasation to the CNS. Sci Rep. 2013;3:1687.
27. Frieser M, Nockel H, Pausch F, Roder C, Hahn A, Deutzmann R, Sorokin LM.
Cloning of the mouse laminin alpha 4 cDNA. Expression in a subset of
endothelium. Eur J Biochem. 1997;246:727–35.
28. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins
from adult hematopoietic cells reveals roles in homeostasis, regeneration,
and homing. Mol Cell Biol. 2003;23:9349–60.
29. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin
oligodendrocyte glycoprotein-specific T cell receptor transgenic mice
develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197:
1073–81.
30. Litzenburger T, Fassler R, Bauer J, Lassmann H, Linington C, Wekerle H,
Iglesias A. B lymphocytes producing demyelinating autoantibodies:
development and function in gene-targeted transgenic mice. J Exp Med.
1998;188:169–80.
31. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte
glycoprotein-specific T and B cells cooperate to induce a Devic-like disease
in mice. J Clin Invest. 2006;116:2393–402.
32. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal
encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B
cell cooperation. J Clin Invest. 2006;116:2385–92.
33. Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia
U, Gross CC, Clausen BE, Weishaupt C, Luger TA, et al. Ultraviolet B light
attenuates the systemic immune response in central nervous system
autoimmunity. Ann Neurol. 2014;75:739–58.
34. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin LM.
Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T
cell recruitment across the blood-brain barrier in experimental autoimmune
encephalomyelitis. J Cell Biol. 2001;153:933–46.
35. Breuer J, Herich S, Schneider-Hohendorf T, Chasan AI, Wettschureck N,
Gross CC, Loser K, Zarbock A, Roth J, Klotz L, et al. Dual action by
fumaric acid esters synergistically reduces adhesion to human
endothelium. Mult Scler. 2017:1352458517735189. https://doi.org/10.
1177/1352458517735189.
36. Schneider-Hohendorf T, Stenner MP, Weidenfeller C, Zozulya AL, Simon OJ,
Schwab N, Wiendl H. Regulatory T cells exhibit enhanced migratory
characteristics, a feature impaired in patients with multiple sclerosis. Eur J
Immunol. 2010;40:3581–90.
37. Ringelmann B, Roder C, Hallmann R, Maley M, Davies M, Grounds M, Sorokin L.
Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and
tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice. Exp Cell Res. 1999;
246:165–82.
Breuer et al. Journal of Neuroinflammation  (2018) 15:236 Page 11 of 12
38. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse
endothelial cell surface marker is suppressed during differentiation of the
blood brain barrier. Dev Dyn. 1995;202:325–32.
39. Korpos E, Kadri N, Kappelhoff R, Wegner J, Overall CM, Weber E, Holmberg
D, Cardell S, Sorokin L. The peri-islet basement membrane, a barrier to
infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes.
2013;62:531–42.
40. Despoix N, Walzer T, Jouve N, Blot-Chabaud M, Bardin N, Paul P, Lyonnet L,
Vivier E, Dignat-George F, Vely F. Mouse CD146/MCAM is a marker of
natural killer cell maturation. Eur J Immunol. 2008;38:2855–64.
41. Stromnes IM, Goverman JM. Active induction of experimental allergic
encephalomyelitis. Nat Protoc. 2006;1:1810–9.
42. Ransohoff RM. A mighty mouse: building a better model of multiple
sclerosis. J Clin Invest. 2006;116:2313–6.
43. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G,
Sorokin LM. Dystroglycan is selectively cleaved at the parenchymal
basement membrane at sites of leukocyte extravasation in experimental
autoimmune encephalomyelitis. J Exp Med. 2006;203:1007–19.
44. Song J, Wu C, Korpos E, Zhang X, Agrawal SM, Wang Y, Faber C, Schafers M,
Korner H, Opdenakker G, et al. Focal MMP-2 and MMP-9 activity at the
blood-brain barrier promotes chemokine-induced leukocyte migration. Cell
Rep. 2015;10:1040–54.
45. Zhang X, Wu C, Song J, Gotte M, Sorokin L. Syndecan-1, a cell surface
proteoglycan, negatively regulates initial leukocyte recruitment to the brain
across the choroid plexus in murine experimental autoimmune
encephalomyelitis. J Immunol. 2013;191:4551–61.
46. Song J, Zhang X, Buscher K, Wang Y, Wang H, Di Russo J, Li L, Lutke-Enking
S, Zarbock A, Stadtmann A, et al. Endothelial basement membrane laminin
511 contributes to endothelial junctional tightness and thereby inhibits
leukocyte transmigration. Cell Rep. 2017;18:1256–69.
47. Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, Robenek H,
Tryggvason K, Song J, Korpos E, et al. Endothelial basement membrane
laminin alpha5 selectively inhibits T lymphocyte extravasation into the
brain. Nat Med. 2009;15:519–27.
48. Schlager C, Korner H, Krueger M, Vidoli S, Haberl M, Mielke D, Brylla E,
Issekutz T, Cabanas C, Nelson PJ, et al. Effector T-cell trafficking between the
leptomeninges and the cerebrospinal fluid. Nature. 2016;530:349–53.
Breuer et al. Journal of Neuroinflammation  (2018) 15:236 Page 12 of 12
